Neutralizing antibodies to HIV-1 GP41 and their use

US11236152B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• The Trustees of Columbia University in the City of New York · US

Inventors

• Peter Kwong · Washington, US
• Young Do Kwon · Bethesda, US
• Ivelin Georgiev · Nashville, US
• Gilad Ofek · Gaithersburg, US
• Baoshan Zhang · Bethesda, US
• Krisha McKee · Columbia, US
• John Mascola · Rockville, US
• Mark Connors · Bethesda, US
• Gwo-Yu Chuang · Rockville, US
• Sijy O'Dell · Silver Spring, US
• Robert Bailer · Adamstown, US
• Mark Louder · Mount Airy, US
• Mangaiarkarasi Asokan · Rockville, US
• Richard Schwartz · Bethesda, US
• Jonathan Michael Cooper · Arlington, US
• Kevin Carlton · Gaithersburg, US
• Michael Bender · Washington, US
• Amarendra Pegu · Potomac, US
• Lawrence Shapiro · New York, US
• Tatyana Gindin · New York, US
• Lisa Kueltzo · Gaithersburg, US

Key dates

• Filing date: Nov 3, 2016
• Grant date: Feb 1, 2022
• Expiry date: Mar 18, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/162
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.